Trial | Target | Treatment vs. control arm | Phase | Setting | Key results (Treatment vs. control) |
---|---|---|---|---|---|
PARP inhibitors targeting germline BRCA-mutated tumors | |||||
OlympiAD [132] | PARP inhibition (olaparib) | Olaparib vs. Chemotherapy (physician’s choice) | III | Metastatic Her2- | PFS 7.0 vs. 4.2 months HR 0.58 (95%CI 0.43–0.80; P < 0.001) |
EMBRACA [133] | PARP inhibition (talazoparib) | Talazoparib vs Chemotherapy (physician’s choice) | III | Metastatic Her2- | PFS 8.6 vs. 5.6 months HR 0.54 (95%CI 0.41–0.71; P < 0.001) |
PARP inhibition (veliparib) | Veliparib + chemotherapy vs Placebo + chemotherapy | III | Metastatic Her2- | PFS 14.5 months vs. 12.6 months HR 0.71 (95%CI 0.57–0.88; P = 0.002) For veliparib vs. placebo as a maintenance monotherapy PFS 25.7 months vs. 14.6 months HR 0.49 (95%CI 0.34–0.73; P < 0.001) | |
OlympiA [136] | PARP inhibition (olaparib) | Olaparib vs. Placebo | III | Adjuvant Her2- | 3-year iDFS 85.9% vs. 77.1% HR 0.58 (95%CI 0.41–0.82; P < 0.001) |
PARP inhibitors targets beyond germline BRCA-mutated tumors | |||||
TBCRC048 [137] | PARP inhibition (olaparib) | Olaparib | II | Metastatic breast cancer Cohort (1): germline mutations in non-BRCA1/2 homologous repair-related genes Cohort (2): somatic mutations in non-BRCA1/2 homologous repair-related genes or somatic BRCA1/2 | Objective response rate 82% among germline PALB2 Objective response rate 50% among somatic BRCA1/2 (primary endpoint met if objective response rate > 20%) |
SWOG S1416 [138] | PARP inhibition (veliparib) | Veliparib + cisplatin vs. Placebo + cisplatin | II | Metastatic TNBC | PFS 5.7 months vs. 4.3 months HR 0.58, P = 0.02 among high HRD tumors |